Fer HE, et al: Peripheral blood mononuclear cells of a patient with sophisticated Hodgkin’s lymphoma give rise to permanently developing Hodgkin-Reed Sternberg cells. Blood 1996, 87(eight):3418?428. 20. Diehl V, Kirchner HH, Schaadt M, Fonatsch C, Stein H, Gerdes J, Boie C: Hodgkin’s illness: establishment and characterization of four in vitro cell lies. J Cancer Res Clin Oncol 1981, 101(1):111?24. 21. Mader A, Bruderlein S, Wegener S, Melzner I, Popov S, Muller-Hermelink HK, Barth TF, Viardot A, Moller P: U-HO1, a new cell line derived from a principal refractory classical Hodgkin lymphoma. Cytogenet Genome Res 2007, 119(three?):204?10. 22. Hsu SM, Zhao X, Chakraborty S, Liu YF, Whang-Peng J, Lok MS, Fukuhara S: Reed-Sternberg cells in Hodgkin’s cell lines HDLM, L-428, and KM-H2 will not be actively replicating: lack of bromodeoxyuridine uptake by multinuclear cells in culture. Blood 1988, 71(5):1382?389. 23. Karp PD, Paley S, Krieger CJ, Zhang P: An proof ontology for use in pathway/genome databases.6-Chloro-1,5-naphthyridin-2(1H)-one Data Sheet In Pacif Sympo Biocomp; 2004:190?01.3-Acrylamidobenzoic acid Chemscene 24. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, et al: Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 2010, 362(ten):875?85. 25. Josting A, Wolf J, Diehl V: Hodgkin disease: prognostic aspects and remedy methods.PMID:34856019 Curr Opin Oncol 2000, 12(5):403?11. 26. Khnykin D, Troen G, Berner JM, Delabie J: The expression of fibroblast growth variables and their receptors in Hodgkin’s lymphoma. J Pathol 2006, 208(three):431?38. 27. Murphy PR, Myal Y, Sato Y, Sato R, West M, Friesen HG: Elevated expression of simple fibroblast growth issue messenger ribonucleic acid in acoustic neuromas. Mol Endocrinol 1989, 3(two):225?31. 28. Tzankov A, Zimpfer A, Pehrs AC, Lugli A, Went P, Maurer R, Pileri S, Dirnhofer S: Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray evaluation of 330 circumstances. Contemporary Pathol J US Can Acad Pathol Inc 2003, 16(11):1141?147. 29. O’Connell FP, Pinkus JL, Pinkus GS: CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol 2004, 121(2):254?63. 30. Carbone A, Gloghini A, Gattei V, Degan M, Improta S, Aldinucci D, Canzonieri V, Perin T, Volpe R, Gaidano G, et al: Reed-Sternberg cells of classical Hodgkin’s illness react together with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Blood 1997, 89(10):3787?794. 31. Costes V, Magen V, Legouffe E, Durand L, Baldet P, Rossi JF, Klein B, Brochier J: The Mi15 monoclonal antibody (anti-syndecan-1) is actually a reputable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol 1999, 30(12):1405?411. 32. Ruotsalainen T, Joensuu H, Mattson K, Salven P: High pretreatment serum concentration of fundamental fibroblast growth aspect is a predictor of poor prognosis in little cell lung cancer. Cancer Epidemiol Biomark Prev Pub Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2002, 11(11):1492?495. 33. Ueno K, Inoue Y, Kawaguchi T, Hosoe S, Kawahara M: Elevated serum levels of basic fibroblast development element in lung cancer sufferers: relevance to response of therapy and prognosis. Lung Cancer 2001, 31(2?):213?19. 34. Salven P, Teerenhovi L, Joensuu H: A higher pretreatment serum fundamental fibroblast development element concentration is an independent predictor of35.36.37.38.39.40.41.42.43.44.45.46.47.48.49.50.51.52.53.poor prognosis in non-Hodgkin’s lymphoma. B.
